Innovations for Heart and Vessels sp. z o.o.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2011-10-14
Share capital
65,600.00 PLN
Average employment (people)
8.6 (2025)
Activity description

Innovations for Heart and Vessels develops InFlow transcatheter aortic valves for TAVI, using biological porcine tissue or biocompatible polymers. The valves offer high biocompatibility, a low risk of calcification and enhanced durability through a proprietary component-joining method, supported by an atraumatic self-positioning delivery system.

Registered address
ul. Ligocka 103, 40-568 Katowice, Poland
Website
Phone
Social media
Electronic delivery address
AE:PL-82378-14961-CJCGC-36

Financials

Revenue history (in k)

From the notes

Profit allocationNo decision
Capital expenditure$2,220,654
Planned capital expenditure (next year)$2,762,431
Revenue structureSprzedaż produktów i usług w kraju
R&D costs$2,505,531
Management board pay$47,966

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 58 days late). 2 of 6 audited by a statutory auditor.

  • 202524/06/2026
  • 202424/06/2025
  • 202319/06/2024
  • 202204/07/2023
  • 202111/09/2022
  • 202027/02/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 49%
City · Katowice4,046 / 6,134
Top 66%
Voivodeship · Śląskie23,045 / 33,241
Top 69%
Country · Poland205,564 / 298,026
Top 69%

Results vs industry

Revenue
This companyUSD 77.00kMedianUSD 73.20kAverageUSD 3.24m
Net profit
This companyUSD -24.22kMedianUSD 69.14AverageUSD 88.42k
Operating costs
This companyUSD 79.91kMedianUSD 76.19kAverageUSD 3.05m
Assets
This companyUSD 11.22mMedianUSD 120.44kAverageUSD 3.91m

Offer

  • Biological aortic valves
  • Polymeric aortic valves
  • Valve implantation systems
  • Preclinical testing

Websites

The site is available in: Polish and English.

  • i4hv.comHome – I4HV – innovations for heart & vessels
    WordPressGoogle AnalyticsGoogle Tag ManagerYoast SEOPolylangCloudflare

Job offers

The company has its own careers page: i4hv.com/careers.

Authorized Representatives

Paweł Eugeniusz Buszman age 65 – President of the Management Board
Piotr Paweł Buszman age 42 – Management Board Member
Piotr Leszek Hirnle age 43 – Management Board Member

Manner of representation

In the case of a multi-member management board, declarations of will, signing documents on behalf of the company and granting powers of attorney require the joint action of two members of the management board, including in every case the President of the Management Board, if appointed, and in the case of a one-person management board, the company is represented independently by the President of the Management Board.

Supervisory board

Aleksander Stefan Wertheim age 77 – Supervisory Board Member
Jan Stanisław Sarna age 78 – Supervisory Board Member
Przemysław Kołodziej age 41 – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
268$7,239.3340.8537%
Fundacja Rodzinna Pro Benefis Familiae
195$5,267.4229.7256%
Others
193$5,213.4029.4207%

Beneficial owners

Person

Subsidiaries

NameStake
Graftflow sp. z o.o.
63.0872%

Sanctions and PEP

Sanctions

No matches (EU, UN, US, UK, MSWiA, World Bank)

PEP

No matches

Bank accounts

Registered as a VAT taxpayer on 2019-07-23.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

10 public aid cases recorded, with a total value of $17,784,105.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$7,563
Aid for research and development projects: experimental development
$6.2M
Regional investment aid
$1.3M

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $18,149,567.

ProjectEU co-financing
Development of production technology and prototypes of polymer valve implants for the transcutaneous and minimally invasive treatment of valve defects
$7.5M
Development of a production technology and prototypes of biological valve implants for transcutaneous and minimally invasive treatment of valvular defects.
$8M
Polymer transcatheter aortic valve implants with a dedicated delivery system
$2.7M

Competitors

Name
Medical Inventi S.A.
Forslab sp. z o.o.
F.R.K. Intra-Cordis sp. z o.o.
Cleardent sp. z o.o.
Nano Prime sp. z o.o.
Integris Medical Polska sp. z o.o.
Astend sp. z o.o.
Medinice S.A.
Dental Nanotechnology S.A.
Biotreat Vascular sp. z o.o.

Change history

DateEvent
2024-06-13Share capital increase
2024-02-15Share capital increase
2023-06-02Share capital increase
2022-04-08Share capital increase
2022-02-18PKD change

FAQ

Last updated: 2026-06-24